Francisella tularensis induces ubiquitin-dependent major histocompatibility complex class II degradation in activated macrophages.
The intracellular bacterium Francisella tularensis survives and replicates within macrophages, ultimately killing the host cell. Resolution of infection requires the development of adaptive immunity through presentation of F. tularensis antigens to CD4+ and CD8+ T cells. We have previously established that F. tularensis induces macrophage prostaglandin E2 (PGE2) production, leading to skewed T-cell responses. PGE2 can also downregulate macrophage major histocompatibility complex (MHC) class II expression, suggesting that F. tularensis-elicited PGE2 may further alter T-cell responses via inhibition of class II expression. To test this hypothesis, gamma interferon (IFN-gamma)-activated reporter macrophages were exposed to supernatants from F. tularensis-infected macrophages, and the class II levels were measured. Exposure of macrophages to infection supernatants results in essentially complete clearance of surface class II and CD86, compromising the macrophage's ability to present antigens to CD4 T cells. Biochemical analysis revealed that infection supernatants elicit ubiquitin-dependent class II downregulation and degradation within intracellular acidic compartments. By comparison, exposure to PGE2 alone only leads to a minor decrease in macrophage class II expression, demonstrating that a factor distinct from PGE2 is eliciting the majority of class II degradation. However, production of this non-PGE2 factor is dependent on macrophage cyclooxygenase activity and is induced by PGE2. These results establish that F. tularensis induces the production of a PGE2-dependent factor that elicits MHC class II downregulation in IFN-gamma-activated macrophages through ubiquitin-mediated delivery of class II to lysosomes, establishing another mechanism for the modulation of macrophage antigen presentation during F. tularensis infection.
Wilson
Justin E
JE
Albany Medical College, Center for Immunology and Microbial Disease, 47 New Scotland Ave., MC-151, Albany, NY 12208, USA.
Katkere
Bhuvana
B
Drake
James R
JR
D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D015153:Blotting, Western; D015232:Dinoprostone / Q000096:biosynthesis / Q000276:immunology; D015536:Down-Regulation; D005434:Flow Cytometry; D005604:Francisella tularensis / Q000276:immunology* / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000276:immunology* / Q000378:metabolism; D047468:Immunoprecipitation; D007371:Interferon-gamma / Q000276:immunology; D008262:Macrophage Activation / Q000276:immunology; D008264:Macrophages / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D051379:Mice; D014406:Tularemia / Q000276:immunology*; D054875:Ubiquitination / Q000276:immunology
D000949:Histocompatibility Antigens Class II; D007371:Interferon-gamma; D015232:Dinoprostone
Infect Immun. 1991 Sep;59(9):2922-8
1879918
Clin Microbiol Rev. 2002 Oct;15(4):631-46
12364373
J Immunol. 2003 Nov 1;171(9):4750-7
14568951
Infect Immun. 2008 Jun;76(6):2651-9
18391003
J Immunol. 2000 Dec 1;165(11):6364-71
11086074
Annu Rev Immunol. 2005;23:975-1028
15771591
J Cell Biol. 2002 Mar 4;156(5):843-54
11864992
FEBS Lett. 2007 Jan 9;581(1):45-51
17174307
Infect Immun. 2008 Jan;76(1):250-62
17984211
J Immunol. 1999 Jan 15;162(2):886-96
9916712
Immunity. 2006 Dec;25(6):885-94
17174123
Blood. 2006 Dec 15;108(13):4086-93
16931624
J Clin Invest. 2001 Jun;107(12):1599-606
11413168
Biochem J. 2003 Oct 1;375(Pt 1):75-86
12841850
Int Immunol. 2001 Feb;13(2):127-34
11157846
J Immunol. 2006 Oct 1;177(7):4299-310
16982864
J Biol Chem. 2008 Oct 17;283(42):28497-505
18713730
Science. 2005 Mar 11;307(5715):1630-4
15761154
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6
10859362
Nature. 1998 Mar 19;392(6673):245-52
9521319
Infect Immun. 2004 Jun;72(6):3204-17
15155622
Microbes Infect. 2003 Feb;5(2):135-42
12650771
J Biol Chem. 2003 Apr 25;278(17):14657-68
12582153
Infect Immun. 1996 Aug;64(8):3288-93
8757866
Cell Biol Int. 2006 Jan;30(1):31-43
16275144
Mol Cell Biol. 2001 Jul;21(14):4626-35
11416140
Annu Rev Cell Dev Biol. 2003;19:141-72
14570567
Immunol Rev. 2005 Oct;207:112-25
16181331
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3491-6
18305173
J Leukoc Biol. 2006 Dec;80(6):1224-30
16908516
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1656-61
18230726
J Immunol. 1996 Dec 1;157(11):5042-8
8943413
Cancer Res. 2007 Apr 15;67(8):3912-8
17440106
Cell Host Microbe. 2007 Mar 15;1(1):77-83
18005683
Immunol Invest. 2004 May;33(2):143-56
15195694
EMBO J. 2002 Feb 1;21(3):251-8
11823418
Dev Cell. 2002 Aug;3(2):283-9
12194858
Blood. 2008 Jan 1;111(1):260-70
17925490
J Virol. 2000 Jun;74(11):5300-9
10799607
Nat Rev Mol Cell Biol. 2002 Dec;3(12):893-905
12461556
Trends Immunol. 2002 Mar;23(3):144-50
11864843
Infect Immun. 2005 May;73(5):2644-54
15845466
J Immunol. 2007 Feb 15;178(4):2065-74
17277110
J Virol. 2004 Feb;78(3):1109-20
14722266
J Immunol. 2006 Jul 1;177(1):341-54
16785530
J Immunol. 2007 Jan 15;178(2):1013-20
17202364
Oncogene. 2004 Mar 15;23(11):2057-70
15021893
Infect Immun. 2006 Jun;74(6):3657-62
16714598
Curr Opin Cell Biol. 2003 Aug;15(4):446-55
12892785
Infect Immun. 1992 Mar;60(3):817-25
1541555
Annu Rev Immunol. 1997;15:749-95
9143706
JAMA. 2001 Jun 6;285(21):2763-73
11386933
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4885-90
8643498
Nature. 2006 Nov 2;444(7115):115-8
17051151
J Immunol. 2007 Jul 1;179(1):532-9
17579074
J Biol Chem. 1991 Apr 15;266(11):7081-6
2016316
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4530-5
15767567
Microb Pathog. 2005 May-Jun;38(5-6):239-47
15925273
Eur J Immunol. 2008 May;38(5):1225-30
18389477
Cell Immunol. 2004 Nov-Dec;232(1-2):75-85
15922718
EMBO J. 2007 Feb 7;26(3):846-54
17255932